Ligand Pharmaceuticals | LGND - Operating Profit



Ligand Pharmaceuticals reported $43.56M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Amgen USD 2.66B 1.37B Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
Baxter International USD 272M 214M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
Glaxosmithkline GBP 2.44B 1.74B Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Ligand Pharmaceuticals USD 43.56M 79.78M Jun/2025
MacroGenics USD -36760000 20.17M Jun/2025
Merck USD 6.36B 494M Jun/2025
Pacira USD 10.23M 8.24M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Veracyte USD 14.31M 13.15M Jun/2025